Overview Dividends

(RLAY) Relay Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75943R1023

PI3Ka Inhibitor, Estrogen Degrader, FGFR Inhibitor, RAS Inhibitor, Fabry Chaperone

RLAY EPS (Earnings per Share)

EPS Growth (3Y CAGR): 45.64%
EPS Trend (3Y Correlation): 72.5%

RLAY Revenue

Revenue Growth (3Y CAGR): 27.91%
Revenue Trend (3Y Correlation): 13.1%

Description: RLAY Relay Therapeutics October 23, 2025

Relay Therapeutics, Inc. (NASDAQ: RLAY) is a clinical-stage precision-medicine company that applies computational protein-motion modeling to accelerate small-molecule discovery for oncology and genetic diseases.

Its flagship pipeline includes:

RLY-2608 – a pan-mutant, isoform-selective PI3Kα inhibitor being evaluated in breast cancer, solid tumors, and vascular malformations, with a current Phase 1/2 trial in combination with fulvestrant and atiprimodiclib (partnered with Pfizer).
RLY-8161 – a targeted inhibitor of RAS-family oncogenic drivers.
RLY-1013 – an estrogen-receptor-α degrader.
Lirafugratinib (RLY-4008) – a receptor-tyrosine-kinase inhibitor for solid-tumor indications, co-developed with Elevar Therapeutics.

Relay leverages strategic collaborations: D. E. Shaw Research provides high-performance molecular dynamics to identify novel conformational states; Elevar Therapeutics co-develops RLY-4008; and Pfizer co-develops RLY-2608 in breast-cancer combos. The company was incorporated in 2015 (originally Allostery, Inc.) and is headquartered in Cambridge, MA.

Key quantitative points (as of the latest 10-Q): cash and marketable securities of ≈ $250 million, giving a runway of roughly 18 months at current burn (~$130 M FY24 R&D expense). The PI3K inhibitor market is projected to exceed $5 billion by 2028, driven by unmet needs in hormone-receptor-positive breast cancer and resistance to first-generation agents. Biotech sector financing remains robust, with Q3-2024 venture capital inflows up 12 % YoY, supporting continued R&D spend for precision-oncology platforms.

For a deeper quantitative view, the ValueRay platform provides a granular, risk-adjusted breakdown of RLAY’s valuation that can help you assess the trade-off between upside potential and execution risk.

RLAY Stock Overview

Market Cap in USD	1,231m
Sub-Industry	Biotechnology
IPO / Inception	2020-07-16

RLAY Stock Ratings

Growth Rating	-46.3%
Fundamental	34.6%
Dividend Rating	-
Return 12m vs S&P 500	-7.43%
Analyst Rating	4.31 of 5

RLAY Dividends

Currently no dividends paid

RLAY Growth Ratios

Growth Correlation 3m	97.6%
Growth Correlation 12m	-1.5%
Growth Correlation 5y	-97%
CAGR 5y	-30.14%
CAGR/Max DD 3y (Calmar Ratio)	-0.33
CAGR/Mean DD 3y (Pain Ratio)	-0.49
Sharpe Ratio 12m	-0.06
Alpha	-19.89
Beta	1.751
Volatility	68.19%
Current Volume	1817.6k
Average Volume 20d	1963.9k
Stop Loss	6 (-8.4%)
Signal	0.38

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-311.5m TTM) > 0 and > 6% of Revenue (6% = 501.4k TTM)

FCFTA -0.36 (>2.0%) and ΔFCFTA 0.71pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 7753 % (prev 1872 %; Δ 5881 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.36 (>3.0%) and CFO -261.4m > Net Income -311.5m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 20.92 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (171.3m) change vs 12m ago 28.94% (target <= -2.0% for YES)

Gross Margin 55.68% (prev 84.38%; Δ -28.69pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 1.11% (prev 4.56%; Δ -3.44pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -6.06 (EBITDA TTM -340.4m / Interest Expense TTM 44.1m) >= 6 (WARN >= 3)

Altman Z'' -36.34

(A) 0.89 = (Total Current Assets 680.4m - Total Current Liabilities 32.5m) / Total Assets 728.8m

(B) -2.59 = Retained Earnings (Balance) -1.89b / Total Assets 728.8m

warn (B) unusual magnitude: -2.59 — check mapping/units

(D) -29.85 = Book Value of Equity -1.89b / Total Liabilities 63.2m

Total Rating: -36.34 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 34.56

1. Piotroski 0.0pt = -5.0

2. FCF Yield -22.76% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.05 = 2.50

5. Debt/Ebitda 0.23 = 2.46

6. ROIC - WACC (= -58.05)% = -12.50

7. RoE -41.49% = -2.50

8. Rev. Trend 13.11% = 0.98

9. EPS Trend 72.51% = 3.63

What is the price of RLAY shares?

As of November 06, 2025, the stock is trading at USD 6.55 with a total of 1,817,583 shares traded.
Over the past week, the price has changed by -10.40%, over one month by +17.17%, over three months by +85.55% and over the past year by +10.08%.

Is Relay Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Relay Therapeutics (NASDAQ:RLAY) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 34.56 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RLAY is around 5.09 USD . This means that RLAY is currently overvalued and has a potential downside of -22.29%.

Is RLAY a buy, sell or hold?

Relay Therapeutics has received a consensus analysts rating of 4.31. Therefore, it is recommended to buy RLAY.

Strong Buy: 6
Buy: 5
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the RLAY price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	13.6	107.6%
Analysts Target Price	13.6	107.6%
ValueRay Target Price	5.9	-10.5%

RLAY Fundamental Data Overview November 04, 2025

Market Cap USD = 1.23b (1.23b USD * 1.0 USD.USD)
P/S = 147.339
P/B = 1.352
Beta = 1.751
Revenue TTM = 8.36m USD
EBIT TTM = -267.4m USD
EBITDA TTM = -340.4m USD
Long Term Debt = 34.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.52m USD (from shortTermDebt, last quarter)
Debt = 34.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -79.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.15b USD (1.23b + Debt 34.2m - CCE 113.9m)
Interest Coverage Ratio = -6.06 (Ebit TTM -267.4m / Interest Expense TTM 44.1m)
FCF Yield = -22.76% (FCF TTM -262.1m / Enterprise Value 1.15b)
FCF Margin = -3136 % (FCF TTM -262.1m / Revenue TTM 8.36m)
Net Margin = -3728 % (Net Income TTM -311.5m / Revenue TTM 8.36m)
Gross Margin = 55.68% ((Revenue TTM 8.36m - Cost of Revenue TTM 3.70m) / Revenue TTM)
Gross Margin QoQ = -48.01% (prev 100.0%)
Tobins Q-Ratio = 1.58 (Enterprise Value 1.15b / Total Assets 728.8m)
Interest Expense / Debt = 20.30% (Interest Expense 6.94m / Debt 34.2m)
Taxrate = 100.0% (out of range, set to none) (-337.7m / -337.7m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 20.92 (Total Current Assets 680.4m / Total Current Liabilities 32.5m)
Debt / Equity = 0.05 (Debt 34.2m / totalStockholderEquity, last quarter 665.7m)
Debt / EBITDA = 0.23 (negative EBITDA) (Net Debt -79.8m / EBITDA -340.4m)
Debt / FCF = 0.30 (negative FCF - burning cash) (Net Debt -79.8m / FCF TTM -262.1m)
Total Stockholder Equity = 750.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.75% (Net Income -311.5m / Total Assets 728.8m)
RoE = -41.49% (Net Income TTM -311.5m / Total Stockholder Equity 750.8m)
RoCE = -34.07% (EBIT -267.4m / Capital Employed (Equity 750.8m + L.T.Debt 34.2m))
RoIC = -45.92% (negative operating profit) (EBIT -267.4m / (Assets 728.8m - Curr.Liab 32.5m - Cash 113.9m))
WACC = 12.13% (E(1.23b)/V(1.27b) * Re(12.47%) + (debt cost/tax rate unavailable))
Discount Rate = 12.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 18.20%
Fair Price DCF = unknown (Cash Flow -262.1m)
EPS Correlation: 72.51 | EPS CAGR: 45.64% | SUE: 4.0 | # QB: 1
Revenue Correlation: 13.11 | Revenue CAGR: 27.91% | SUE: 0.07 | # QB: 0

Additional Sources for RLAY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle